Fate of Thrombin and Thrombin-Antithrombin-III Complex Adsorbed to a Heparinized Biomaterial: Analysis of the Enzyme-Inhibitor Complexes Displaced by Plasma

Summary

Heparin covalently-linked to polyvinyl alcohol (PVA) is a biomaterial which is of potential value as a non-thrombogenic coating. ¹²⁵I-labelled thrombin adsorbed to heparin-PVA beads was not dislodged by phosphate-buffered saline, pH 7.4, although radioactivity was progressively displaced from the adsorbent by fibrinogen-free human plasma. Analysis by gel filtration and affinity chromatography showed that the released radioactivity was distributed between (thrombin-antithrombin-III) complex (approx. 70%) and, probably, (thrombin-α-2-macroglobulin) complex (approx. 30%). Less efficient thrombin displacement was obtained by either bovine serum albumin (5% w/v) or antithrombin-III-free human plasma: in the latter case, the dislodged enzyme was presumably associated with α-2-macroglobulin. Purified α-2-macroglobulin did not displace thrombin from heparin-PVA. The quantity of thrombin displaced by an α- 2-macroglobulin-free plasma fraction compared well with fibrinogen-free plasma: The eluted enzyme was largely associated with antithrombin-III. Purified antithrombin-III did not displace thrombin from heparin-PVA despite causing >70% inactivation of the bound enzyme. Subsequent treatment with fibrinogen-free plasma dislodged (thrombin-antithrombin-III) at a similar rate to that of bound thrombin. We conclude that plasma contains a component(s) which displaces (thrombin-antithrombin-III) complex from immobilised heparin: presumably this leaves the heparin sites free for further use in enzyme inactivation.

Keywords

Heparinized biomaterial - Thrombin - Antithrombin-III - α-2-Macroglobulin - (Thrombin-inhibitor) complexes

• References

• 1 Merrill EW, Salzman EW, Wong PS L, Ashford TD, Brown AH, Austen WG. Polyvinyl alcohol-heparin hydrogel “G”. J Appl Physiol 1970; 29: 723-730
• 2 Goosen MF, Sefton MV. Heparinised styrene-butadiene-styrene elastomers. J Biomed Mater Res 1979; 13: 347-364
• 3 Goosen MF A, Sefton MV, Hatton MW C. Inactivation of thrombin by antithrombin-III on a heparinized biomaterial. Thromb Res 1980; 20: 543-554
• 4 Cholakis CH, Sefton MV. Chemical characterization of an immobilized heparin: heparin-PVA. A.C.S. Division of Polymer Chemistry Polymer Preprint: 1983. 24 64-65
• 5 Basmadjian D, Sefton MV. Relationship between release rate and surface concentration for heparinized biomaterials. J Biomed Mater Res 1983; 17: 509-518
• 6 Goosen MF, Sefton MV. The fate of surface-bound heparin. Adv Chem 1982; 199: 147-160
• 7 Goosen MF, Sefton MV. Properties of a heparin-polyvinyl alcohol hydrogel coating. J Biomed Mater Res 1983; 17: 359-373
• 8 Hatton MW, Regoeczi E. The inactivation of thrombin and plasmin by antithrombin-III in the presence of Sepharose-heparin. Thromb Res 1977; 10: 645-660
• 9 Hatton MW, Kaur H, Regoeczi E. The effect of heparin adsorbed on Sepharose-lysine on the inactivation of thrombin by antithrombin- III. Biochem Soc Trans 1977; 5: 1443-1446
• 10 Lundblad RL, Uhteg LC, Vogel CN, Kingdon HS, Mann KG. Preparation and partial characterisation of two forms of bovine thrombin. Biochem Biophys Res Commun 1975; 66: 482-489
• 11 Hatton MW, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin-III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-670
• 12 Hatton MW C. Studies on the coagulant enzyme from Ancistrodon rhodostoma venom: Isolation and some properties of the enzyme. Biochem J 1973; 131: 799-807
• 13 Hatton MW, Regoeczi E. Some observations on the affinity chromatography of rabbit plasminogen. Biochim Biophys Acta 1974; 359: 55-65
• 14 Mitchell GA, Hudson PM, Huseby RM, Pochron SP, Gargrilo RJ. Fluorescent substrate assay for antithrombin-III. Thromb Res 1978; 12: 219-225
• 15 Harpel PC. Human α-2-macroglobulin. Meth Enzymol 1976; 45: 639-652
• 16 Collen D, De Cock F, Verstraete M. Quantitation of thrombin-antithrombin-III complexes in human blood. Eur J Clin Invest 1977; 7: 407-411
• 17 Miller-Anderson M, Borg H, Andersson LO. Purification of anti-thrombin-III by affinity chromatography. Thromb Res 1974; 5: 439-452
• 18 Pepper DS, Banhegyi D, Cash JD. The different forms of antithrombin-III in serum. Thromb Haemostas 1977; 38: 494-503
• 19 Binder B. On the complex formation of antithrombin-III with thrombin. Gel filtration studies on human plasma and serum Thrombos Diathes Haemorrh 1973; 30: 280-283
• 20 Marciniak E, Gora-Maslak G. High molecular weight forms of antithrombin III complexes in blood. Thromb Haemostas 1983; 49: 32-36
• 21 Shapiro SS, Anderson DB. Thrombin inhibition in normal plasma. In: Chemistry and Biology of Thrombin. Lundblad RL, Fenton JW, Mann KG. (Eds.) Ann Arbor Science Publishers Inc; Ann Arbor, Mich: 1977. pp 361-374
• 22 Lam LS L, Regoeczi E, Hatton MW C. In vivo behaviour of some antithrombin-III-protease complexes. Br J Exp Pathol 1979; 60: 151-160
• 23 Danielsson A, Bjork I. Slow, spontaneous dissociation of the anti-thrombin-thrombin complex produces a proteolytically modified form of the inhibitor. FEBS Lett 1980; 119: 241-244
• 24 Fish WW, Orre K, Bjork I. The production of an inactive form of antithrombin through limited proteolysis by thrombin. FEBS Lett 1979; 98: 103-106
• 25 Marciniak E. Thrombin-induced proteolysis of human antithrombin- III: an outstanding contribution of heparin. Br J Haematol 1981; 48: 325-336